Phenol, 4,4'-(9H-fluoren-9-ylidene)bis-

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Descriptors
• Chemical-gene interaction
• Chemical-phenotype interaction
• Chemical-disease association
• ToxCast endpoints
• Associated AOPs
• Presence in consumer products
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:31082581	IVR	50 mg/kg/day	50 mg/kg/day	Oxidative stress in ovaries	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Affects folliculogenesis	Reproductive endocrine-mediated perturbations
	IVR	50 mg/kg/day	50 mg/kg/day	Induce apoptosis of ovarian follicles	Reproductive endocrine-mediated perturbations
	IVR	2 mg/kg/day	2 mg/kg/day	Oxidative stress in ovaries	Reproductive endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Induce apoptosis of ovarian follicles	Reproductive endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Oxidative stress in ovaries	Reproductive endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Affects folliculogenesis	Reproductive endocrine-mediated perturbations
PMID:35987080	IVTH	0.00000001 - 0.00004 M	0.00000001 - 0.00004 M	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
	IVTH	0.00002 - 0.00003 M	0.00002 - 0.00003 M	Decreased aldosterone levels	Metabolic endocrine-mediated perturbations
	IVTH	0.00002 - 0.00003 M	0.00002 - 0.00003 M	Decrease in cortisol levels	Neurological endocrine-mediated perturbations
	IVTH	0.00000001 M	0.00000001 M	Increased testosterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.000001 M	0.000001 M	Increased estradiol levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 - 0.00003 M	0.00001 - 0.00003 M	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00003 M	0.00003 M	Decreased estradiol levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00003 M	0.00003 M	Affects glucose metabolism	Metabolic endocrine-mediated perturbations
PMID:37816402	IVTH	0.0000000001 - 0.00001 M	0.0000000001 - 0.00001 M	Cancer phenotype	Endocrine-mediated cancer
PMID:37939739	IVTH	0.000001 - 0.0001 M	0.000001 - 0.0001 M	Decreased progesterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0001 M	0.0001 M	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
PMID:38123054	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Reduced sperm counts	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Increased testis weights	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Induce behavioral changes	Neurological endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Affects sperm motility	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Changes in testicular morphology	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Affects spermatogenesis	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Affects blood-testis barrier (BTB)	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Oxidative stress in testis	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Induce ferroptosis in testis	Reproductive endocrine-mediated perturbations
	IVR	1 - 5 mg/kg/day	1 - 5 mg/kg/day	Decreased body weights	Metabolic endocrine-mediated perturbations
PMID:38573577	IVR	0.5 - 5 mg/kg/day	0.5 - 5 mg/kg/day	Changes in brain morphology	Neurological endocrine-mediated perturbations
	IVR	5 mg/kg/day	5 mg/kg/day	Induce behavioral changes	Neurological endocrine-mediated perturbations
	IVR	5 mg/kg/day	5 mg/kg/day	Affects social behavior	Neurological endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg/day	0.5 - 5 mg/kg/day	Affects neuronal signaling	Neurological endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg/day	0.5 - 5 mg/kg/day	Affects neuronal function	Neurological endocrine-mediated perturbations
PMID:38844314	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Affects circadian rhythm	Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Changes in liver morphology	Hepatic endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Elevated glucose levels	Metabolic endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Decreased body weights	Metabolic endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Affects sexual behavior	Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Induce behavioral changes	Neurological endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Causes inflammation	Immunological endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Exhibit sexual dimorphism	Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Decreased estradiol levels	Reproductive endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Decreased growth hormone (GH) levels	Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Increased triglycerides level	Metabolic endocrine-mediated perturbations
	IVR	5 mg/kg	5 mg/kg	Increased Aspartate aminotransferase (AST) levels	Hepatic endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	0.5 - 5 mg/kg	0.5 - 5 mg/kg	Affects liver function	Hepatic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.